GlassScriptPhysician profile
Martha E Benavides
NPI 1215105580
$6,285.50
in general payments reported to CMS, 2019-2025
25 companies · $2,178 in 2025
The $2,178 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $79.13 · 2022: $1,256 · 2023: $1,515 · 2024: $1,257 · 2025: $2,178.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,950.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,950.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $999.02 | 2023-2025 | Tezspire |
| Abbott Laboratories | $866.04 | 2021-2023 | Freestyle Libre 3, Thoratec Heartmate 3 Lvas Implant Kit |
| Novo Nordisk INC | $604.43 | 2022-2025 | |
| Teva Pharmaceuticals USA, INC. | $478.75 | 2022-2025 | Ajovy, Austedo Xr |
| Gilead Sciences, INC. | $345.59 | 2024-2025 | Yeztugo, Epclusa, Biktarvy |
| Alnylam Pharmaceuticals INC. | $344.27 | 2024 | Amvuttra, Givlaari |
| Daiichi Sankyo INC. | $318.69 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $269.78 | 2023-2024 | Spravato, Xarelto |
| Tandem Diabetes Care, INC. | $196.31 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Mallinckrodt Hospital Products INC. | $191.88 | 2025 | Terlivaz |
| Mannkind Corporation | $171.28 | 2023 | Afrezza |
| Medtronic, INC. | $144.78 | 2023 | Intellis Adaptivestim |
| Sequel Med Tech, LLC | $142.20 | 2025 | Twiist |
| Spr Therapeutics, INC | $133.18 | 2025 | Sprint Pns System |
| Incyte Corporation | $130.82 | 2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $124.94 | 2023 | |
| Amylyx Pharmaceuticals, INC. | $121.87 | 2023 | Relyvrio |
| Neurocrine Biosciences, INC. | $121.38 | 2025 | |
| Alkermes, INC. | $114.39 | 2025 | Vivitrol |
| Chiesi USA, INC. | $99.98 | 2022 | |
| Exact Sciences Corporation | $98.14 | 2023 | Cologuard Collection Kit |
| Biogen, INC. | $94.48 | 2022 | |
| Scynexis, INC. | $92.05 | 2022 | |
| Horizon Therapeutics Plc | $48.26 | 2022 | |
| Abbvie INC. | $32.99 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Martha Benavides listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.